World Journal of Gastroenterology - Baishideng Publishing Group

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 29, Issue 10

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7357)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-2) series.

Item

Count

PDF

508

WORD

HTML

4046

Tables (1-2)

633

Sum=5223

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

277

Download

692

Sum=969

Publishing Process of This Article

Item

Count

Browse

350

Download

817

Sum=1167

Mar 14, 2023 (publication date) through Mar 25, 2026

Times Cited of This Article

Times Cited (11)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Cited by in CrossRef

For:	Cheah E, Huang JG. Precision medicine in inflammatory bowel disease: Individualizing the use of biologics and small molecule therapies. World J Gastroenterol 2023; 29(10): 1539-1550 [PMID: 36970587 DOI: 10.3748/wjg.v29.i10.1539]
URL:	https://www.wjgnet.com/1007-9327/full/v29/i10/1539.htm

Number	Citing Articles
1	Bernardo de Faria Moraes, Gustavo André Pedral Diniz Leite, Luisa Medeiros Visentini, Gabriel André Pedral Diniz Leite, Igor Boechat Silveira, Valbert Oliveira Costa Filho, Luis Pedro Possapp Beis, Leonardo Corrêa Süffert, Pedro Robson Costa Passos, Guilherme Grossi Lopes Cançado. Safety of advanced therapies in pregnant women with inflammatory bowel disease: a systematic review and Meta-Analysis. Journal of Crohn's and Colitis 2026; 20(3) doi: 10.1093/ecco-jcc/jjag035
2	Pooja Kushwaha, Rahila Qureshi, Nooruddin Khan, Sangita Mukhopadhyay. Revolutionizing IBD therapy: Insights into contemporary treatment strategies. International Reviews of Immunology 2026; 45(1): 1 doi: 10.1080/08830185.2025.2563522
3	Sidsel Støy, Silvia D’Alessio, Thomas Damgaard Sandahl, Anders Dige, Anne Louise Kjølbye, Rasmus Jorgensen, Silvio Danese, Martijn van de Bunt. Lipidated IL-22 Alone or Combined with Immunomodulatory Agents Improves Disease Endpoints and Promotes Mucosal Healing in a Mouse Model of Chronic Dextran Sodium Sulfate-Induced Colitis. Digestive Diseases and Sciences 2025; 70(6): 2021 doi: 10.1007/s10620-025-09007-w
4	Xiaona Yang, Hong Guo, Min Zou. Inflammatory bowel diseases: pathological mechanisms and therapeutic perspectives. Molecular Biomedicine 2026; 7(1) doi: 10.1186/s43556-025-00395-z
5	Luyao Liu, Fan Zhao, Dandan Han, Xin Lü, Gang Wu, Yanglei Yi. Liquiritigenin ameliorates DSS-induced ulcerative colitis by improving intestinal barrier function, reducing endoplasmic reticulum stress and modulating gut microbiota. Journal of Functional Foods 2024; 122: 106541 doi: 10.1016/j.jff.2024.106541
6	Shi-Yan Zhang. Navigating new horizons in inflammatory bowel disease: Integrative approaches and innovations. World Journal of Gastroenterology 2024; 30(41): 4411-4416 doi: 10.3748/wjg.v30.i41.4411 Abstract(678) \| Core Tip(656) \| Full Article(HTML)(2365) \| Full Article with Cover (PDF)-1855K(192) \| Audio-1001K(13) \| Peer-Review Report-176K(109) \| Answering Reviewers-400K(242) \| Full Article (PDF)-371K(172) \| Full Article (XML)-84K(105) \| Times Cited (1) \| Total Visits (5639) \| Open
7	Hua Huang, Jiaze Ma, An Kang, Tianwei Guo, Wei Sun, Yan Xu, Lijiang Ji. Investigating the molecular mechanisms associated with ulcerative colitis through the application of single-cell combined spatial transcriptome sequencing. Frontiers in Immunology 2025; 16 doi: 10.3389/fimmu.2025.1534768
8	Andrzej S Tarnawski. Editor-in-Chief articles of choice and comments at the year-end of 2023. World Journal of Gastroenterology 2024; 30(1): 1-8 doi: 10.3748/wjg.v30.i1.1 Abstract(1088) \| Core Tip(1053) \| Full Article(HTML)(4672) \| Full Article with Cover (PDF)-1825K(385) \| Full Article (Word)-130K(43) \| Audio-14227K(33) \| Peer-Review Report-222K(197) \| Answering Reviewers-194K(152) \| Full Article (PDF)-407K(293) \| Full Article (XML)-119K(181) \| Times Cited (0) \| Total Visits (14624) \| Open
9	Danny Con, Peter De Cruz. Defining management strategies for acute severe ulcerative colitis using predictive models: a simulation-modeling study. Intestinal Research 2024; 22(4): 439 doi: 10.5217/ir.2023.00175
10	Fang-Yuan Zheng, Kai-Si Yang, Wen-Cheng Min, Xin-Zhu Li, Yu Xing, Shuai Wang, Ying-Shi Zhang, Qing-Chun Zhao. Is tumor necrosis factor-α monoclonal therapy with proactive therapeutic drug monitoring optimized for inflammatory bowel disease? Network meta-analysis. World Journal of Gastrointestinal Surgery 2024; 16(2): 571-584 doi: 10.4240/wjgs.v16.i2.571 Abstract(563) \| Core Tip(663) \| Full Article(HTML)(1756) \| Full Article with Cover (PDF)-2615K(138) \| Full Article (Word)-1431K(8) \| Audio-2064K(4) \| Peer-Review Report-254K(115) \| Answering Reviewers-134K(106) \| Supplementary Material-222K(103) \| Full Article (PDF)-2359K(168) \| Full Article (XML)-155K(168) \| Times Cited (0) \| Total Visits (7599) \| Open
11	Daniel Schweckendiek, Gerhard Rogler. Antibodies Targeting the Tumor Necrosis Factor-Like Ligand 1A in Inflammatory Bowel Disease: A New Kid on the (Biologics) Block?. Digestion 2024; 105(6): 411 doi: 10.1159/000540421